The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 356:1580-1581 April 12, 2007 Number 15
NextNext

Sunitinib and Hypothyroidism

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Motzer, R. J.
-PubMed Citation
To the Editor: In their study of sunitinib versus interferon alfa in the treatment of metastatic renal-cell carcinoma, Motzer et al. (Jan. 11 issue)1 report that a high proportion of patients in both study groups had grade 3 or 4 fatigue. We wonder whether hypothyroidism could be a possible explanation and whether thyroid function was evaluated. Interferon can cause thyroid dysfunction,2 and there is growing evidence that sunitinib also causes abnormalities in thyroid function.3,4,5 In our group of 65 patients who were treated with sunitinib for renal-cell carcinoma or gastrointestinal stromal tumors, the incidence of laboratory evidence of thyroid dysfunction . . . [Full Text of this Article]


This article has been cited by other articles:


HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.